A Study to Investigate Safety of INT2104 Infusions in Participants Aged 18 Years of Age and Older Who Have B-cell Cancers That Came Back After Previous Treatment

Inclusion Criteria:

• Diagnosed with relapsed/refractory (R/R) B-NHL (Burkitt's lymphoma are eligible forPart B only) confirmed by histology or flow cytometry Note: Bone Marrow involvementis allowed

• B-NHL must have CD20 antigen positive tumour confirmed from a tumour biopsy taken atscreening

• Measurable disease at the time of enrolment

• Progression after at least 2 lines of systemic therapy

• Has not received more than one prior marketed CAR-T cell therapy (including tandemor bispecific CAR-T) or other genetically modified T-cell therapy.

• Sex and Contraceptive/Barrier Requirements consistent with local regulations forclinical trials Females: must have negative serum pregnancy test at screening and onDay -1 prior to INT2104 infusion Both sexes: must agree to use highly effectivemethods, including a barrier method after INT2104 infusion

• Haematological criteria:

• Absolute lymphocyte count (ALC) ≥300/µL

• Platelet count ≥50,000/mL

• Absolute neutrophil count (ANC) ≥500/µL

• Eastern Cooperative Oncology Group (ECOG) score of 0 or 1

• Adequate renal, cardiac, hepatic, and lung function

Key Inclusion Part B only

• Diagnosed with relapsed/refractory B-ALL, and with exceptions as detailed inexclusion criteria. Participants with Philadelphia chromosome positive (Ph+) B-ALLdisease are eligible.

• B-ALL participants must have CD20 antigen positive leukaemia

• Measurable disease at the time of enrolment

• Participants with Burkitt's lymphoma are eligible for Part B only

Exclusion Criteria:

• Central Nervous System (CNS)-only B-cell malignancy, or B-cell malignancy with R/Rsecondary CNS involvement.

• Diagnosis or history of chronic lymphocytic leukaemia (CLL) (including large cell [Richter] transformation of CLL) or small lymphocytic lymphoma (SLL)

• Diagnosis or history of cutaneous lymphoma

• History of another primary malignancy that has not been in remission for at least 3years before signing informed consent (except for: non-melanoma skin cancer, lowgrade prostate cancer or carcinoma in situ (e.g., cervix, bladder, breast))

• Acute or chronic graft-versus-host disease

• Participant has received donor lymphocyte infusion within 6 weeks prior to INT2104infusion

• History of autoimmune disease requiring systemic immunosuppression/ systemic diseasemodifying agents within 2 years before enrolment

• History or presence of CNS disorder

• History of myocardial infarction, cardiac angioplasty or stenting, unstable angina,or other clinically significant cardiac disease within 12 months before signinginformed consent

• Participants has active syphilis, cytomegalovirus (CMV), acute or chronic activehepatitis B, or untreated hepatitis C.

• Participant is Human immunodeficiency virus (HIV) positive.

• Any medical condition likely to interfere with assessment of safety or efficacy ofthe study treatment

• A vaccine within 4 weeks prior to INT2104 infusion

• Intolerance or severe hypersensitivity reaction to any excipients of the INT2104product.

• An active fungal, bacterial, viral, or other infection that is uncontrolled orrequires antimicrobials at the time of INT2104 infusion.

• Participant is pregnant or nursing.

• In the investigator's judgment, the participant is unlikely to complete allprotocol-required study visits or procedures, including follow-up visits, or complywith the study requirements for participation

Note: Other protocol defined Inclusion/Exclusion criteria may apply.